Odatroltide demonstrated potential in reperfusion-ineligible AIS patients, who currently face significant unmet medical needs.

BERLIN, Jan 27 (Reuters) - Swiss pharmaceutical firm Roche said on Tuesday that a phase II clinical trial of its experimental ...

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

The target for commercialization is 2030. The indication will also be expanded to diabetes. The company received related ...

SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NNVC) (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health ...

SHANGHAI, Feb 9 (Reuters) - China's Innovent Biologics has struck a new deal with Eli Lilly to develop immunology and oncology drugs, under which the U.S. drugmaker will pay $350 million upfront and ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated, a dermatologist-founded, late clinical-stage biopharmaceutical company developing potentially first-in-class therapeutics for common ...

ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease LOS ANGELES, CA / ...

Patients dosed with an experimental Skye Bioscience obesity drug did not lose enough weight to meet the goals of a mid-stage study, dealing a setback to the biotech’s bid to revive a class of ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Thursday announced that the FDA has granted the company's request for an End of Phase 2 meeting to discuss its proposed clinical development plan and seek ...

SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE ...

GSK is expanding its prospects in hepatology, paying $1.2 billion to acquire a drug that goes after a clinically validated liver target but with a dosing advantage that could give it a competitive ...